What does a KRAS G12C-positive result mean?

It means the cancer sample tested contains a specific KRAS mutation in which codon 12 has changed from glycine to cysteine. This matters because KRAS G12C is a target for certain newer drugs, especially in advanced non-small cell lung cancer. The result does not by itself decide treatment; the cancer type, stage, prior treatment, and other biomarkers also matter.

Which cancers are most likely to have KRAS G12C?

KRAS G12C is most often discussed in non-small cell lung cancer, where it is found in about 12% of cases according to review data. It is less common in colorectal cancer at roughly 3% and in pancreatic ductal adenocarcinoma at about 1.5%. The exact frequency can vary by study population and testing method.

How is KRAS G12C testing done?

Testing is usually done on tumour tissue using next-generation sequencing or a PCR-based assay. In some patients, a blood-based liquid biopsy can detect KRAS G12C from circulating tumour DNA. If a liquid biopsy is negative, doctors may still recommend tissue testing because some tumours do not shed enough DNA into blood.

Does KRAS G12C mean targeted treatment is available?

Sometimes, yes, but it depends on the cancer type and treatment setting. In previously treated advanced NSCLC, KRAS G12C inhibitors such as sotorasib or adagrasib have shown clinical activity and may be options where approved and available. In colorectal cancer, responses are often better with combination treatment, such as pairing KRAS G12C inhibition with EGFR-directed therapy.

If my report says only 'KRAS mutation,' should I ask for more detail?

Yes. KRAS is a family of different mutations, and the exact subtype can change treatment options. Asking whether the report specifies variants such as G12C, G12D, or G12V is especially important in advanced lung cancer and can also matter in colorectal cancer. If the original test was limited, your oncologist may suggest broader molecular profiling.

KRAS G12C mutation — Glossary | India Cancer Guide

What it is

KRAS G12C mutation is a specific KRAS gene change in which glycine at codon 12 is replaced by cysteine; it occurs in about 12% of non-small cell lung cancers (NSCLC). It is an actionable biomarker because it can help guide treatment, especially in advanced NSCLC, and it may also be relevant in colorectal cancer and a smaller fraction of other solid tumours. In standard mutation notation, it may be written as KRAS p.G12C or c.34G>T depending on the reporting format.

KRAS is part of the RAS-MAPK signaling pathway, which helps control cell growth and survival. When KRAS carries an activating mutation such as G12C, the protein can remain abnormally switched on, sending growth signals that support cancer development. Not every KRAS mutation is the same. G12C is one subtype, and its clinical meaning differs from other KRAS variants such as G12D or G12V.

For patients and families, the key point is simple: KRAS G12C testing is done to look for a targetable mutation that may open the door to specific medicines. The result is usually reported from tumour tissue by next-generation sequencing or PCR-based testing, and in some settings it can also be detected in blood through a liquid biopsy.

Term on report	What it means
KRAS p.G12C	Protein-level notation showing glycine (G) changed to cysteine (C) at codon 12
KRAS c.34G>T	DNA-level notation for the underlying nucleotide change
KRAS G12C positive	The mutation was detected
KRAS G12C negative	This specific mutation was not detected

How it works

KRAS is a small GTPase that acts like a molecular switch. In normal cells, it cycles between an active and inactive state. The G12C mutation alters the protein so that signaling through downstream pathways such as MAPK and PI3K becomes dysregulated, promoting tumour growth and survival.

What made KRAS G12C especially important in oncology is that the mutant protein contains a cysteine residue that can be targeted by newer drugs. This allowed the development of KRAS G12C inhibitors such as sotorasib and adagrasib, which bind selectively to the mutant KRAS protein in its inactive GDP-bound state. These drugs do not treat all KRAS-mutant cancers. They are designed for the G12C subtype only.

The effect of a KRAS G12C mutation also depends on the cancer type and on other co-existing mutations. For example, response patterns in NSCLC are not identical to those in colorectal cancer, where feedback signaling through EGFR can limit activity of KRAS G12C inhibitors unless combination strategies are used.

Evidence and uses

KRAS G12C is most clinically established as a predictive biomarker in advanced NSCLC. Reviews cited in the literature report KRAS G12C in roughly 12% of NSCLC, around 3% of colorectal cancers, and about 1.5% of pancreatic ductal adenocarcinomas. Within KRAS-mutant NSCLC, G12C is one of the most common subtypes.

The main current uses of KRAS G12C testing are:

To identify eligibility for targeted therapy in advanced or metastatic cancers, especially NSCLC.
To refine molecular classification of the tumour.
To help with treatment sequencing after standard therapies such as chemotherapy or immunotherapy.
To support clinical trial matching for combination strategies and newer inhibitors.

In the phase 2 CodeBreaK 100 study in previously treated KRAS p.G12C-mutated advanced NSCLC, sotorasib showed meaningful antitumor activity and led to regulatory approvals in several countries. This established KRAS G12C as a practical treatment target, not just a research finding. Adagrasib has also shown activity in KRAS G12C-mutated NSCLC and in some patients with colorectal cancer, particularly in combination approaches.

In colorectal cancer, KRAS G12C is less common but still important. Evidence suggests it may be associated with poorer prognosis in some settings, and targeted treatment often works better when KRAS G12C inhibition is paired with EGFR blockade rather than used alone. This is an area of active research.

In India, the practical issue is access to broad molecular profiling. Large cancer centres increasingly use next-generation sequencing panels for lung cancer and some gastrointestinal cancers, but availability and cost can vary. If a pathology report only says "KRAS mutant" without naming the subtype, patients may need to ask whether the exact variant, such as G12C, was identified.

Diagnosis / how it's measured

KRAS G12C is not diagnosed by symptoms or imaging. It is measured by a molecular test on cancer tissue or circulating tumour DNA.

Common testing methods include:

Method	Sample	Main use
Next-generation sequencing (NGS)	Tumour tissue or blood	Broad profiling; detects KRAS subtype and other mutations
PCR-based assay	Tumour tissue, sometimes blood	Faster targeted detection of known variants
Liquid biopsy	Blood	Useful when tissue is limited or repeat biopsy is difficult

Testing is usually ordered in people with advanced NSCLC, and may also be considered in metastatic colorectal cancer or other solid tumours depending on the clinical setting. Results should be interpreted with the full pathology and molecular profile, because co-mutations and tumour type affect treatment choices.

A negative liquid biopsy does not always rule out KRAS G12C. If blood testing is negative but suspicion remains high, tissue testing may still be needed because some tumours shed little DNA into the bloodstream.

When to see a clinician

Ask your oncologist about KRAS G12C testing if you or your family member has:

Advanced or metastatic NSCLC
Metastatic colorectal cancer
A pathology report showing KRAS mutation without the exact subtype
Disease progression after initial treatment, when new targeted options or trials are being considered

It is also reasonable to ask whether testing was done on tissue, blood, or both, and whether the report included other biomarkers such as EGFR, ALK, ROS1, BRAF, MET, RET, HER2, and PD-L1 in lung cancer. Treatment decisions should be made with a medical oncologist familiar with molecular oncology, because the presence of KRAS G12C does not automatically mean the same drug is appropriate for every cancer type.

Limitations and open questions

KRAS G12C is an important biomarker, but it has limits. First, it is only one subtype of KRAS mutation, so a drug that works for G12C will not necessarily work for G12D, G12V, or other KRAS variants. Second, even when KRAS G12C inhibitors work, cancers can develop acquired resistance through additional pathway changes or alternative signaling routes.

Another limitation is that evidence is strongest in NSCLC and is still evolving in other tumours. In colorectal cancer, for example, single-agent activity is more limited, and combination therapy is often needed. Evidence in pancreatic and other solid tumours is more restricted and often based on smaller studies.

Testing quality also matters. Small biopsy samples, low tumour content, or low circulating tumour DNA can lead to false-negative results. Access remains uneven across health systems, including in India, where comprehensive genomic testing may not be available in every centre.

Research is ongoing on earlier-line use, combination regimens, brain metastasis activity, resistance mechanisms, and next-generation KRAS inhibitors. That means a KRAS G12C result is highly useful, but it should be interpreted as part of a broader and changing treatment picture.

KRAS G12C mutation